Highly selective and sensitive sandwich immunosensor platform modified with MUA-capped GNPs for detection of spike Receptor Binding Domain protein: A precious marker of COVID 19 infection

A label-free electrochemical biosensing system as a suitable analysis technique for COVID 19 specific spike receptor-binding domain protein (RBD) was developed with an aim to facilitate the diagnosis of coronavirus. A novel production procedure for the fabrication of gold nanoparticles (GNPs)-capped 11-mercaptoundecanoic acid (MUA) modified bioelectrode was presented and its application potential for RBD biosensing was examined. The bioelectrode fabrication protocol was based on covalent ester linking formation between hydroxylated ITO electrode and GNPs-capped MUA (GNPs@MUA) with carboxyl ends. For this aim, spherical GNPs were prepared and characterized with scanning-transmission electron microscopy (S-TEM), UV–vis, and Raman spectroscopy. The synthesized GNPs were functionalized with MUA yielding Au-S bonds. Then, covalent immobilization of anti-RBD antibodies on the GNPs@MUA was performed with the help of carbodiimide coupling chemistry. The assembly processes of GNPs@MUA, anti-RBD antibodies and RBD antigens were characterized electrochemical, chemical and morphological techniques. GNPs@MUA was used as immobilization environment and provided the most effective surface design for target immunosensor. The resulting immunosensor is further applied to the impedimetric detection of RBD and it displayed a linear response to RBD antigen in the linear range of 0.002−100 pg mL(−1) with a limit of detection of 0.577 fg mL(−1) and sensitivity of 0.238 kohmpgmL(−1) cm(−2). The fabricated immunosensor had a good repeatability, long storage, stability and a reusable property after simple regeneration process. Furthermore, it was successfully employed for selective determination of RBD in artificial nasal secretion samples.